- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Gland Pharma has announced a board meeting to review its financial results for the quarter and nine months ended December 31, 2024. The company reported a total revenue from operations of ₹13,840.52 million and utilized expenses amounting to ₹11,432.44 million, leading to a profit before tax of ₹2,993.02 million. The net profit for the period stands at ₹2,046.92 million. This earnings report underscores a sound performance, despite losses from its subsidiaries, which may cause some investor caution. Overall, this update could be viewed positively due to the company's operational stability and revenue generation potential.